Weight Clinical Trials in Dallas, Texas
29 recruitingDallas, Texas
Showing 1–20 of 29 trials
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled774 locationsNCT07037433
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Pfizer3,501 enrolled170 locationsNCT07311850
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Type 2 Diabetes Mellitus (T2DM)Obese or Overweight Healthy Volunteers
Alnylam Pharmaceuticals144 enrolled22 locationsNCT06845202
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled169 locationsNCT07321886
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
ObesityOverweight
Eli Lilly and Company600 enrolled35 locationsNCT07357415
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityOverweight
Eli Lilly and Company900 enrolled180 locationsNCT07392190
Recruiting
Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ObesityDiabetes Mellitus, Type 2Overweight
Eli Lilly and Company200 enrolled42 locationsNCT07215559
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight
Hoffmann-La Roche2,000 enrolled73 locationsNCT07351045
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled61 locationsNCT07351058
Recruiting
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company1,481 enrolled53 locationsNCT06143956
Recruiting
Phase 1
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
ObesityHealthyOverweight+1 more
Eli Lilly and Company216 enrolled5 locationsNCT06945419
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
ObesityOverweight
Eli Lilly and Company600 enrolled80 locationsNCT06972459
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company1,200 enrolled80 locationsNCT06993792
Recruiting
Not Applicable
Comparing Outcomes Among Children With Obesity in a Community Healthy Lifestyle Program
Pediatric ObesityOverweight/ObesityPediatric Overweight
University of Texas Southwestern Medical Center160 enrolled1 locationNCT07342855
Recruiting
Not Applicable
Neonatal Platelet Transfusion Threshold Trial
ThrombosisThrombocytopeniaNeonatal+4 more
NICHD Neonatal Research Network2,433 enrolled20 locationsNCT06676904
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company250 enrolled31 locationsNCT07232719
Recruiting
Phase 3
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Weight Loss
Viking Therapeutics, Inc.1,100 enrolled134 locationsNCT07104383
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company600 enrolled77 locationsNCT06972472
Recruiting
Follow-up Visit of High Risk Infants
Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational Age+1 more
NICHD Neonatal Research Network68,000 enrolled31 locationsNCT00009633